In this study, we want to determine if dietary intervention is feasible for patients being treated for leukemia or lymphoma.

In this study, we want to find out if a combination of 3 different study drugs (Cabozantinib, Ipilimumab, and Nivolumab) will affect the progression of Soft Tissue Sarcoma.

Have you been diagnosed with metastatic triple negative breast cancer and have had progression of your cancer during or following your most recent cancer treatment? If so, you may be eligible for a study looking at the combination of two investigational drugs with doxil for patients with metastatic triple negative breast cancer.

Have you been diagnosed with relapsed or refractory multiple myeloma? If so you may be able to take part in a research study looking at the safety and efficacy of giving BMS-986393 to patients with multiple myeloma.

The main purpose of the study is to determine whether the study drug, ONC-392, together with a standard of care drug PLUVICTO® (Lutetium Lu 177 Vipivotide Tetraxetan), are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with the standard of care PLUVICTO® alone.

The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.

Have you been diagnosed with Lateralized Oropharyngeal Cancer . If so, you may be able to take part in a research study looking at the safety by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT) compared to the usual treatment when radiotherapy is given .

Do you have pancreatic ductal adenocarcinoma that has come back after receiving standard therapy? If so, you may be able to participate in this gene therapy research study to learn more about using you own modified immune cells as possible treatment.

This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.

Have you been diagnosed with early stage triple negative breast cancer? We are asking you to take part in this research study because you have been diagnosed with triple-negative breast cancer (TNBC) and have recently completed preoperative chemotherapy in combination with pembrolizumab, followed by breast surgery. The chemotherapy plus pembrolizumab produced a pathologic complete response (pCR), meaning that no remaining cancer was found during your breast surgery.